SBI Securities’s Sagimet Biosciences SGMT Stock Holding History

SBI Securities’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$682	Sell	69 -48	-41%	-$441	﹤0.01%	3005
2026 Q2	$904	Buy	117 +33	+39%	+$224	﹤0.01%	2839
2026 Q1	$439	Buy	84 +60	+250%	+$334	﹤0.01%	2935
2025 Q4	$142	Sell	24 -12	-33%	-$86	﹤0.01%	3310
2025 Q3	$247	Buy	36 +26	+260%	+$211	﹤0.01%	3248
2025 Q2	$76	Sell	10 -112	-92%	-$473	﹤0.01%	3615
2025 Q1	$398	Buy	122 +83	+213%	+$348	﹤0.01%	2957
2024 Q4	$176	Buy	+39	New	+$198	﹤0.01%	3284

Other funds holding SGMT

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

SBI Securities's SGMT Position: Q3 2026 in Review

SBI Securities reduced its Sagimet Biosciences (SGMT) stake by 41% in Q3 2026, selling an estimated $441 and leaving 69 shares worth $682. The position accounts for ﹤0.01% of the portfolio, ranked #3005.

SBI Securities first reported a position in SGMT in Q4 2024 and has held it in 8 quarters since. The position peaked at $904 in Q2 2026. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

SBI Securities held 69 shares of Sagimet Biosciences worth $682 as of Q3 2026.
SBI Securities sold 48 Sagimet Biosciences shares in Q3 2026, an estimated $441.
Sagimet Biosciences made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3005 holding.
SBI Securities first reported a position in Sagimet Biosciences in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Sagimet Biosciences position peaked at $904 in Q2 2026.
63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.